CRBPCorbus Pharmaceuticals Hold...

Nasdaq corbuspharma.com


$ 39.74 $ 0.95 (2.45 %)    

Tuesday, 07-May-2024 15:59:52 EDT
QQQ $ 440.32 $ 0.07 (0.02 %)
DIA $ 388.70 $ 0.29 (0.07 %)
SPY $ 517.26 $ 0.57 (0.11 %)
TLT $ 90.79 $ 0.55 (0.61 %)
GLD $ 214.23 $ -0.99 (-0.46 %)
$ 39.77
$ 38.26
$ 0.00 x 0
$ 0.00 x 0
$ 38.26 - $ 40.26
$ 3.03 - $ 49.87
160,046
na
330.51M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-12-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-08-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-12-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-08-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-12-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-28-2016 12-31-2015 10-K
35 11-10-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 05-13-2015 03-31-2015 10-Q
38 02-10-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 corbus-pharmaceuticals-q1-eps-083-beats-152-estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate o...

 corbus-announces-dosing-of-first-patient-in-us-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc

Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumors Emerging clinical profile f...

 oppenheimer-reiterates-outperform-on-corbus-pharmaceuticals-raises-price-target-to-58

Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION